Value-Based R&D Pharma Productivity 2015: Oncology And Hep C Drive Top Performers
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.
You may also be interested in...
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
The superior R&D and growth performance of mid-sized companies like Celgene, Gilead, or Biogen can be attributed to a number of factors such as the size of the R&D budget, portfolio focus, a good mix of internal and external innovation sourcing, but most importantly a strong culture, leadership, and the ability to attract the right people. Part 3 of Catenion’s review of pharma R&D productivity.
The reorganizations of pharmaceutical R&D organizations has failed to address fundamental issues that afflict R&D across several industries. Most of this shortfall can be attributed to a dearth of effective leadership within the C-suites of the drug industry.